Claudin-18.2 targeting by zolbetuximab: results of SPOTLIGHT in perspective
- 15 April 2023
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 401 (10389) , 1630-1631
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialThe Lancet, 2023
- Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancerESMO Open, 2023
- Preclinical activity for TPX-4589 (LM-302), an antibody-drug conjugate targeting tight junction protein CLDN18.2 in solid tumorsEuropean Journal of Cancer, 2022
- Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal CancerJAMA Oncology, 2022
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancerBMC Medicine, 2022
- Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim resultsNature Medicine, 2022
- Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction AdenocarcinomasJournal of Personalized Medicine, 2021
- Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerScientific Reports, 2019
- The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysisJNCI: Journal of the National Cancer Institute, 2016